Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a
clinical stage biopharmaceutical company focused on developing
multimodal biological immunotherapies to help patients fight
cancer, today announced it will be hosting a webcasted R&D
breakfast panel featuring prominent scientific and medical thought
leaders to discuss topline overall survival data from its phase 2
clinical trial of CAN-2409, its multimodal biological immunotherapy
candidate, in Non-Small Cell Lung Cancer (NSCLC).
The event will be held on Monday, June 3, 2024,
at 7:00 AM Central Time, during the 2024 American Society of
Clinical Oncology (ASCO) Annual Meeting in Chicago.
Paul Peter Tak, MD, PhD, FMEDSci,
President and Chief Executive Officer of Candel, will be
hosting the event and moderating the guest panel, which
includes:
- Charu Aggarwal, MD, MPH,
FASCO Leslie M. Heisler Associate Professor for Lung
Cancer Excellence, Perelman School of Medicine, University of
Pennsylvania
- Roy S. Herbst, MD,
PhD Chief of Medical Oncology Yale School of Medicine
Candel Research Advisory Board
- Daniel H. Sterman, MD,
FCCP, ATSF, DAABIP Professor and Director, Pulmonary,
Critical Care and Sleep Medicine NYU Langone Health
A live webcast will be available by selecting
Events and Presentations, under the News & Events tab, in the
Investors section on Candeltx.com. A replay of the webcast
will be archived for up to 90 days following the session
date.
EDITOR’S NOTE: Media
representatives interested in attending the event should please
contact Kyle Evans at CandelPR@westwicke.com.
About CAN-2409
CAN-2409, Candel’s most advanced multimodal
biological immunotherapy candidate, is an investigational,
off-the-shelf, replication-defective adenovirus designed to deliver
the herpes simplex virus thymidine kinase (HSV-tk) gene to a
patient’s specific tumor and induce an individualized, systemic
anti-tumor immune response. HSV-tk is an enzyme that locally
converts orally administered valacyclovir into a toxic metabolite
that kills nearby cancer cells. Together, this regimen is designed
to induce an individualized and specific CD8+ T cell mediated
response against the injected tumor and uninjected distant
metastases for broad anti-tumor activity, based on in situ
vaccination against a variety of tumor antigens. Because of its
versatility, CAN-2409 has the potential to treat a broad range of
solid tumors. Encouraging monotherapy activity as well as
combination activity with standard of care radiotherapy, surgery,
chemotherapy, and immune checkpoint inhibitors have previously been
shown in several preclinical and clinical settings. Furthermore,
more than 1,000 patients have been dosed with CAN-2409 with a
favorable tolerability profile to date, supporting the potential
for combination with other therapeutic strategies without
inordinate concern of overlapping adverse events.
Currently, Candel is evaluating the effects of
treatment with CAN-2409 in NSCLC, borderline resectable pancreatic
ductal adenocarcinoma (PDAC), and localized, non-metastatic
prostate cancer in ongoing clinical trials. CAN-2409 plus prodrug
(valacyclovir) has been granted Fast Track Designation by the U.S.
Food and Drug Administration (FDA) for treatment of stage III/IV
NSCLC in patients who are resistant to first line PD-(L)1 inhibitor
therapy and who do not have activating molecular driver mutations
or have progressed on directed molecular therapy, treatment of
borderline resectable PDAC, and treatment of localized prostate
cancer. The FDA has also granted Orphan Drug Designation to
CAN-2409 for the treatment of PDAC. The Company’s pivotal phase 3
clinical trial in prostate cancer is being conducted under a
Special Protocol Assessment by the FDA.
About Candel Therapeutics
Candel is a clinical stage biopharmaceutical
company focused on developing off-the-shelf multimodal biological
immunotherapies that elicit an individualized, systemic anti-tumor
immune response to help patients fight cancer. Candel has
established two clinical stage multimodal biological immunotherapy
platforms based on novel, genetically modified adenovirus and
herpes simplex virus (HSV) gene constructs, respectively. CAN-2409
is the lead product candidate from the adenovirus platform and is
currently in ongoing clinical trials in NSCLC (phase 2), borderline
resectable PDAC (phase 2), and localized, non-metastatic prostate
cancer (phase 2 and phase 3). CAN-3110 is the lead product
candidate from the HSV platform and is currently in an ongoing
phase 1b clinical trial in recurrent high-grade glioma (rHGG). In
October 2023, the Company announced that Nature published results
from this ongoing clinical trial. Finally, Candel’s enLIGHTEN™
Discovery Platform is a systematic, iterative HSV-based discovery
platform leveraging human biology and advanced analytics to create
new viral immunotherapies for solid tumors. The Company presented
preclinical data at the AACR Annual Meeting in April 2024,
unveiling the second candidate from this platform, a first-in-class
multimodal immunotherapy candidate to induce tertiary lymphoid
structures (TLS), being developed as a novel therapeutic for solid
tumors.
For more information about Candel, visit:
www.candeltx.com.
Forward-Looking Statements
This press release includes certain disclosures
that contain “forward-looking statements,” within the meaning of
the Private Securities Litigation Reform Act of 1995, as amended,
including, without limitation, express or implied statements
regarding the timing and advancement of the Company’s development
programs, including key data readout presentations; expectations
regarding the therapeutic benefit of the Company’s programs; and
the ability of CAN-2409 to improve the median overall survival of
patients with NSCLC. The words “may,” “will,” “could,” “would,”
“should,” “expect,” “plan,” “anticipate,” “intend,” “believe,”
“estimate,” “predict,” “project,” “potential,” “continue,” “target”
and similar expressions are intended to identify forward-looking
statements, although not all forward-looking statements contain
these identifying words. Any forward-looking statements in this
press release are based on management’s current expectations and
beliefs and are subject to a number of risks, uncertainties and
important factors that may cause actual events or results to differ
materially from those expressed or implied by any forward-looking
statements contained in this press release, including, without
limitation, those risks and uncertainties related to the timing and
advancement of development programs; the Company’s ability to
continue as a going concern; expectations regarding the therapeutic
benefit of the Company’s programs; that final data from the
Company’s pre-clinical studies and completed clinical trials may
differ materially from reported interim data from ongoing studies
and trials; the Company’s ability to efficiently discover and
develop product candidates; the Company’s ability to obtain and
maintain regulatory approval of product candidates; the Company’s
ability to maintain its intellectual property; the implementation
of the Company’s business model, including strategic plans for the
Company’s business and product candidates; and other risks
identified in the Company’s filings with the U.S. Securities and
Exchange Commission (SEC) including the Company’s most recent
Quarterly Report on Form 10-Q filed with the SEC and subsequent
filings with the SEC. The Company cautions you not to place undue
reliance on any forward-looking statements, which speak only as of
the date they are made. The Company disclaims any obligation to
publicly update or revise any such statements to reflect any change
in expectations or in events, conditions, or circumstances on which
any such statements may be based, or that may affect the likelihood
that actual results will differ from those set forth in the
forward-looking statements. Any forward-looking statements
contained in this press release represent the Company’s views only
as of the date hereof and should not be relied upon as representing
its views as of any subsequent date.
Investor Contact: Theodore
Jenkins VP, Investor Relations and Business Development
Candel Therapeutics, Inc. tjenkins@candeltx.com
Media Contact:Kyle EvansICR Westwicke
CandelPR@westwicke.com
Candel Therapeutics (NASDAQ:CADL)
Historical Stock Chart
From May 2024 to Jun 2024
Candel Therapeutics (NASDAQ:CADL)
Historical Stock Chart
From Jun 2023 to Jun 2024